Abstract: The oral administration to genetically alcoholic rats (from the strain UChB of the University of Chile) of a compound selected from endogenic polyamines (putrescine, spermidine, spermine), 1,3-propanediamine, their pharmaceutically acceptable salts and solvates, and their bioprecursor amides, causes a significant reduction in the alcohol consumption. The activity lasts for some time after the treatment period. Besides, there is a virtually null disulfiram-like adverse effect, what constitutes an advantage over the unpleasant use of some anti-alcoholism agents, such as calcium cyanamide or disulfiram itself. Therefore, the compounds of the invention are useful for the preparation of medicaments for the therapeutic and/or prophylactic treatment of alcoholism in human beings.
Type:
Grant
Filed:
September 19, 2002
Date of Patent:
June 19, 2007
Assignee:
Garbil Pharma Investigacion Chile Ltda.
Inventors:
Norberto Bilbeny Lojo, Hernan Garcia Madrid
Abstract: N,N?-bis(3-aminopropyl)cyclohexane-1,4-diamine, of formula (I), is a new compound that is prepared by hydrogenation with Raney nickel catalyst of N,N?-bis(2-cyanoethyl)-cyclohexane-1,4-diamine, the latter being prepared by reaction between 1,4-cyclohexanediamine and acrylonitrile. The oral administration to genetically alcoholic rats (from the strain UChB of the University of Chile) of the tetrametanesulfonate monohydrate of (I) causes a significant reduction in the alcohol consumption. The activity lasts for some time after the treatment period. Besides, there is a virtually null disulfiram-like adverse effect, what constitutes an advantage over the unpleasant use of some anti-alcoholism agents, such as calcium cyanamide or disulfiram itself.
Type:
Grant
Filed:
July 1, 2002
Date of Patent:
April 11, 2006
Assignee:
Garbil Pharma Investigacion Chile Ltda.
Inventors:
Norberto Bilbeny Lojo, Hernan Garcia Madrid, Maria Belen Font Arellano